Poorer Survival of Male Breast Cancer Compared with Female Breast Cancer Patients May Be Due to Biological Differences
Poorer Survival of Male Breast Cancer Compared with Female Breast Cancer Patients May Be Due to Biological Differences
复制标题
DOI：
10.1093/jjco/hyt116
复制
发表时间：
2013-10-01
影响因子：
2.4
通讯作者：
Tong, Zhongsheng
中科院分区：
文献类型：
--
作者：
Chen, Xingyu;Liu, Xiaodong;Tong, Zhongsheng
该研究的目的是比较一组匹配的男性和女性乳腺癌患者的无病生存率和总生存率，并分析可能的治疗和性别相关差异。回顾性分析我院1980年12月至2012年6月收治的150例可手术男性乳腺癌患者的资料。数据库中记录的每位男性乳腺癌患者与两名相同分期的女性乳腺癌患者相匹配。评估无病生存期和总生存期的预后。男性平均诊断年龄58.69.7岁，女性平均诊断年龄57.2 10.3岁。中位随访时间为男性69个月，女性81个月。两组患者在肿瘤位置、激素受体状态、分子亚型和激素治疗方面均存在显著差异。单因素分析显示，肿瘤大小、淋巴结状态、美国癌症联合委员会分期、分子亚型和辅助化疗是影响男性乳腺癌患者预后的因素。5年和10年无病生存率男性分别为65.6和40.1，女性分别为74.9和51.5。男性5年和10年的总生存率分别为72.9和53.9，女性为83.2和68.5。两组患者无病生存期和总生存期差异有统计学意义（P < 0.002）。男性乳腺癌患者虽然分期相同，但与匹配的女性乳腺癌患者相比，预后较差，这表明生物学差异可能是导致预后较差的原因。
The objective of the study was to compare disease-free survival and overall survival in a group of matched males and females with breast cancer, and to analyze possible treatment- and gender-related differences.We retrospectively analyzed the data of 150 operable male breast cancer patients treated in our hospital from December 1980 to June 2012. Each male breast cancer patient recorded in the database was matched with two female breast cancer patients of equal stage. Prognosis in terms of disease-free survival and overall survival was evaluated.The mean age at diagnosis was 58.6 9.7 years for males and 57.2 10.3 years for females. The median follow-up was 69 months for males and 81 months for females. Significant differences were identified for tumor location, hormone receptor status, molecular subtypes and hormone therapy between the two groups. Monofactorial analysis demonstrated that tumor size, lymph node state, American Joint Committee on Cancer stage, molecular subtypes and adjuvant chemotherapy treatment were prognostic factors in male breast cancer patients. The 5- and 10-year disease-free survival rates were 65.6 and 40.1 for males, and 74.9 and 51.5 for females, respectively. The 5- and 10-year overall survival rates were 72.9 and 53.9 for males, and 83.2 and 68.5 for females, respectively. There was significantly difference in disease-free survival and overall survival between the two matched groups (P 0.002).Male breast cancer patients had inferior outcome despite of equal stage in comparison with matched female breast cancer patients, which demonstrates that biological differences may contribute to the worse prognosis.